MTOR and melanoma: Although trials of single agent mTOR inhibition produced a 0% stable disease rate, preliminary results in a phase I trial of CCI-779 and HCQ in patients with all solid tumors showed a 74% stable disease rate in melanoma patients at first restaging [54].